The survey data highlights a distinct threshold where patient comfort breaks down whenever automated clinical decision-making displaces human oversight. Only twenty-seven percent of surveyed consumers strongly trust automated systems to accurately detect and flag potential drug-drug or drug-disease interactions without a healthcare professional directly involved. Demonstrating defensive behavior against perceived algorithmic error, sixty-eight percent of consumers state they would independently verify medication details, pill counts, or dosages always or most of the time if generated through processes utilizing artificial intelligence.
This demand for human guidance becomes pronounced in clinical dialogue. When discussing drug adverse events and complex side effects, fifty-nine percent of consumers prefer interacting exclusively with a healthcare professional, with another thirty-three percent preferring a hybrid model, while a mere eight percent prefer interacting solely with a digital or AI tool.
A parallel divide appears across physical and digital dispensing channels. While eighty-six percent of consumers express comfort receiving medications through traditional retail pharmacies and seventy-eight percent via health plan benefit programs, that confidence plummets to thirty-five percent for fully automated kiosks or self-service dispensary lockers. This friction persists even as health systems deploy automated kiosks, such as adherent360 partnerships, to compress discharge dispensing times to five minutes or less.
While consumer sentiment remains cautious, enterprise healthcare leaders face their own structural obstacles when scaling generative AI and automated decision trees. Nearly all surveyed professionals—ninety-eight percent—expect their organizations’ dependence on curated, continuously maintained medication intelligence to increase as automation accelerates. When asked what is most critical to build confidence in AI adoption, thirty-six percent cited greater confidence in underlying therapeutic and medication intelligence, and twenty-three percent cited stronger governance and reviewability, while only nine percent prioritized access to larger volumes of raw medication data.
Source link
